Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance
TPST-1120 demonstrated monotherapy clinical benefit in patients with late-line advanced, poor-prognosis cancers where responses would be unexpectedRECIST responses observed with...
Cellbxhealth PLC Announces Holding(s) in Company